Your browser is no longer supported. Please, upgrade your browser.
VTGN VistaGen Therapeutics, Inc. daily Stock Chart
VTGN [NASD]
VistaGen Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.25 Insider Own7.31% Shs Outstand22.92M Perf Week-0.73%
Market Cap31.17M Forward P/E- EPS next Y-0.59 Insider Trans0.00% Shs Float21.23M Perf Month-6.85%
Income-15.60M PEG- EPS next Q-0.14 Inst Own13.40% Short Float10.84% Perf Quarter25.93%
Sales0.00M P/S- EPS this Y27.30% Inst Trans-0.68% Short Ratio2.55 Perf Half Y11.48%
Book/sh0.30 P/B4.53 EPS next Y9.10% ROA-203.80% Target Price22.00 Perf Year-22.73%
Cash/sh0.45 P/C3.00 EPS next 5Y- ROE-418.60% 52W Range0.69 - 2.65 Perf YTD22.15%
Dividend- P/FCF- EPS past 5Y46.50% ROI- 52W High-48.68% Beta-0.75
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin- 52W Low97.10% ATR0.10
Employees9 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)52.80 Volatility9.17% 6.40%
OptionableNo Debt/Eq0.01 EPS Q/Q41.10% Profit Margin- Rel Volume0.10 Prev Close1.35
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume902.82K Price1.36
Recom2.00 SMA20-1.13% SMA505.18% SMA20015.40% Volume89,634 Change0.74%
Jun-27-18Initiated Maxim Group Buy $6
Feb-08-18Reiterated Chardan Capital Markets Buy $30 → $22
Mar-28-17Initiated Maxim Group Buy $4
Jun-26-18 05:12PM  VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights GlobeNewswire
Jun-20-18 07:05AM  Breakfast Technical Briefing on Tesaro and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-13-18 08:30AM  VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101 GlobeNewswire +5.67%
Jun-11-18 08:30AM  VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders GlobeNewswire
May-29-18 07:30AM  Mayo Clinic-Backed NMTC Could Be Worth 3X This Year ACCESSWIRE -10.20%
May-25-18 01:03PM  Why Vistagen Therapeutics Inc Stock Is Going Wild Today InvestorPlace +51.55%
09:43AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
May-24-18 05:05PM  Oppenheimer Feels Positive About VistaGen's 'Best-In-Class' Antidepressant, Sets $6 Target Benzinga
May-23-18 08:30AM  VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage GlobeNewswire
May-02-18 08:30AM  VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101 GlobeNewswire
Apr-10-18 08:30AM  VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101 Marketwired
Apr-05-18 08:00AM  VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder Marketwired
Mar-19-18 10:17AM  VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101 Marketwired
Mar-07-18 09:00AM  VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101 Marketwired
Mar-05-18 09:02AM  VistaGen Therapeutics to Present at Oppenheimer's 28th Annual Healthcare Conference on March 21, 2018 Marketwired +6.35%
Feb-27-18 08:30AM  VistaGen Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference on March 14, 2018 Marketwired
Feb-12-18 04:30PM  VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results Marketwired
Jan-29-18 04:15PM  VistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive Disorder Marketwired
Jan-22-18 08:30AM  VistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets' Investor Conference Marketwired +9.10%
Jan-03-18 08:30AM  VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder Marketwired
Dec-22-17 01:04PM  [$$] Susquehanna: 3 Microcap Stocks It's Buying and 1 Mid-Cap Barrons.com
Dec-18-17 08:30AM  VistaGen Therapeutics to Present at the 10th Annual Biotech Showcase Marketwired
Dec-13-17 04:30PM  VistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common Stock Marketwired
Dec-12-17 07:30AM  Wired News VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem Cells ACCESSWIRE
Dec-11-17 09:25AM  VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock Marketwired -32.22%
Dec-08-17 02:22PM  3 Drug/Biotech Stocks Up More Than 10% This Week Zacks -11.33%
09:00AM  VistaGen Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Patent on Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer Marketwired
Dec-07-17 08:05AM  VistaGen Soars on Patent Announcement, Pipeline Review, and Analysts Opinion ACCESSWIRE +12.78%
08:00AM  Todays Research Reports on Stocks to Watch: Madrigal Pharmaceuticals and VistaGen Therapeutics ACCESSWIRE
Dec-06-17 02:54PM  Vistagen Therapeutics Inc (VTGN) Wows Investors with a New Patent Victory SmarterAnalyst +95.65%
09:08AM  VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101 Marketwired
Nov-09-17 04:30PM  VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update Marketwired
Nov-06-17 08:30AM  VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of Depression Marketwired +20.51%
Nov-03-17 12:49PM  Is VistaGen Therapeutics Incs (VTGN) Balance Sheet A Threat To Its Future? Simply Wall St.
Oct-26-17 07:30AM  VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder Marketwired
Oct-04-17 12:26PM  Should You Worry About VistaGen Therapeutics Inc (VTGN) Cash Runway? Simply Wall St.
Sep-28-17 08:00AM  VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent Regarding Methods of Production for AV-101 Marketwired
Sep-25-17 10:05AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by VistaGen Therapeutics, Inc. Business Wire
Sep-06-17 04:15PM  VistaGen Announces Closing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock Marketwired +5.39%
Aug-31-17 09:10AM  VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock Marketwired
Aug-21-17 09:00AM  VistaGen Therapeutics Expands VistaStem's Scientific Advisory Board with Appointment of Medicinal Chemistry Expert, David Rotella, PhD Marketwired
Aug-14-17 04:05PM  VistaGen Therapeutics Reports First Fiscal Quarter 2018 Financial Results and Provides Business Update Marketwired
Aug-08-17 08:30AM  VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer Marketwired +5.11%
Jul-10-17 08:30AM  VistaGen Therapeutics Appoints Dr. Mark Wallace to Clinical Advisory Board to Advance AV-101 as a Potential Non-Opioid Treatment for Neuropathic Pain Marketwired +6.08%
Jun-29-17 08:30AM  VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update Marketwired
Jun-22-17 08:30AM  VistaGen Announces Peer-Reviewed Publication in the Scandinavian Journal of Pain Highlighting Orally-Available AV-101's Excellent Safety Profile and Potential as a Non-Opioid Treatment for Neuropathic Pain Marketwired
May-01-17 08:00AM  VistaGen Therapeutics' Largest Stockholder Signs 6-Month Lock-Up Agreement Marketwired +12.12%
Apr-27-17 09:00AM  VistaGen Therapeutics Announces Peer-Reviewed Publication in The Journal of Pain Highlighting AV-101's Potential for Treating Neuropathic Pain Marketwired
Mar-29-17 04:18PM  VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events +11.96%
09:00AM  VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101 Marketwired
Mar-28-17 07:44AM  Coverage initiated on VistaGen by Maxim Group
Mar-10-17 03:17PM  VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Mar-08-17 09:00AM  VistaGen Therapeutics to Ring the Nasdaq Stock Market Closing Bell on Monday, March 13, 2017 Marketwired -5.24%
Feb-17-17 01:04PM  VISTAGEN THERAPEUTICS, INC. Financials
Feb-13-17 04:31PM  VISTAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
04:15PM  VistaGen Therapeutics Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update Marketwired
Jan-10-17 01:50PM  Vistagen Therapeutics Inc (VTGN) Finds Stem Cell Partner In Bayer AG (ADR) (BAYRY) With Phase II TRD Data On Tap Insider Monkey
01:50PM  Vistagen Therapeutics Inc (VTGN) Finds Stem Cell Partner In Bayer AG (ADR) (BAYRY) With Phase II TRD Data On Tap at Insider Monkey
Jan-05-17 09:33AM  VistaGen Therapeutics to Present at Biotech Showcase 2017 PR Newswire
Dec-14-16 08:01AM  VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events -6.32%
07:05AM  VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell Technologies to BlueRock Therapeutics PR Newswire
Nov-30-16 07:05AM  VistaGen Therapeutics to Present at 9th Annual LD Micro Main Event PR Newswire
Nov-22-16 03:22PM  Small-Cap Biotech Is on Front Lines of Fight Against Depression GuruFocus.com
Nov-15-16 06:25AM  VISTAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-14-16 05:24PM  VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:15PM  VistaGen Therapeutics Reports Second Quarter 2017 Financial Results and Business Update PR Newswire
Oct-21-16 05:04PM  VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Oct-04-16 07:00AM  VistaGen Therapeutics Appoints Mark A. McPartland Vice President of Corporate Development and Investor Relations PR Newswire
Sep-27-16 05:16PM  VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.